Methods: We performed genome-wide homozygosity mapping, whole-exome and Sanger sequencing, immunophenotyping studies, and analysis of genotoxic stress responses. p38 activation, reactive oxygen species levels, rate of apoptosis and clonogenic survival, and growth in immune and nonimmune cells were assessed. The outcome of allogeneic hematopoietic stem cell transplantation (HSCT) was monitored. Results: We report 2 patients with progressive BMF associated with myelodysplastic features, immunodeficiency affecting B cells and neutrophil granulocytes, and complex developmental aberrations, including mild skeletal anomalies, neurocognitive developmental delay, and cataracts. Whole-exome sequencing revealed a homozygous premature stop codon mutation in the gene encoding MYSM1. MYSM1-deficient cells are characterized by increased sensitivity to genotoxic stress associated with sustained induction of phosphorylated p38 protein, increased reactive oxygen species production, and decreased survival following UV light-induced DNA damage. Both patients were successfully treated with allogeneic HSCT with sustained reconstitution of hematopoietic defects. Conclusions: Here we show that MYSM1 deficiency is associated with developmental aberrations, progressive BMF with myelodysplastic features, and increased susceptibility to genotoxic stress. HSCT represents a curative therapy for patients with MYSM1 deficiency. (J Allergy Clin Immunol 2017;140:1112-9.)
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Inherited bone marrow failure (BMF) syndromes comprise a heterogeneous group of disorders associated with dysfunction of hematopoietic stem or progenitor cells. Genetic analysis of these rare diseases has provided important insight into the fundamental biological principles governing genomic integrity in stem cells, such as DNA repair, telomere maintenance, or ribosomal biogenesis. 1 Although the hierarchical control of hematopoiesis by transcription factors is well studied, the relevance of epigenetic regulation remains less well understood. Myb-like, SWIRM, and MPN domains 1 (MYSM1) has originally been identified in a search for transcriptional regulators and was found to mediate histone deubiquitination, specifically at position lysine 119 (K119) of histone 2A (H2A), a common chromatin modification associated with gene silencing. 2 Targeted deletion of murine Mysm1 results in severe hematopoietic defects associated with an early block of B-cell development 3 ; dysfunction of stem cell maintenance, self-renewal, and differentiation 4 ; and natural killer (NK) cell defects. 5 In human subjects exome sequencing studies have revealed potentially disease-causing mutations in MYSM1 in 2 families with BMF and immunodeficiencies. 6, 7 Here we study 2 patients with MYSM1 deficiency, including genetic reconstitution data and cellular studies illustrating decreased genotoxic stress resistance in patients with this rare genetic disorder.
METHODS

Patient information and study approval
Patients were referred to the Department of Pediatrics, Al-Sabah Hospital, Kuwait, and the Dr. von Hauner Children's Hospital at Ludwig-MaximiliansUniversit€ at Munich, Germany. Informed consent was obtained according to current ethical and legal guidelines. This study was conducted in accordance with the Declaration of Helsinki and was approved by the institutional review board of the Ludwig-Maximilians-Universit€ at Munich.
Next-generation sequencing and genetic analysis
Next-generation sequencing was performed, as previously described. 8 Briefly, genomic DNA isolated from whole blood of both patients and their parents were first analyzed with the Affymetrix Genome-wide Human SNP array 6.0 (GEO Platform GPL6801), according to the manufacturer's instructions (Affymetrix, Santa Clara, Calif). Remaining DNA has been used for generation of whole-exome libraries using the SureSelect XT Human All Exon V4 1 UTRs kit (Agilent Technologies, Santa Clara, Calif). Barcoded libraries were sequenced with the SOLiD 5500 XL next-generation sequencing platform (Life Technologies, Grand Island, NY) to an average coverage depth of 80. Bioinformatic analysis and subsequent filtering of called variants led to identification of a potentially causative homozygous mutation (see Table  E1 in this article's Online Repository at ww.jacionline.org). All relevant variants were confirmed by using Sanger sequencing.
Cell culture
Epstein-Barr virus transformed B lymphoblastoid cell lines (EBV-LCLs) were generated by infecting freshly isolated PBMCs with B95-8 cell supernatant in the presence of cyclosporine and maintained in RPMI 1640 medium supplemented with 10% heat-inactivated FBS, 1% penicillin/streptomycin, 1% HEPES, and 2 mmol/L L-glutamine at 378C in the presence of 5% CO 2 . Fibroblasts were derived from skin or foreskin biopsy specimens, with continuous cultivation in Dulbecco modified Eagle medium and supplementation with 10% heat-inactivated FBS, 1% penicillin/streptomycin, and 2 mmol/L L-glutamine at 378C in a 5% CO 2 atmosphere.
Further clinical data and methods are provided in the Methods section in this article's Online Repository at ww.jacionline.org.
RESULTS
Clinical phenotype
We studied 2 siblings of a consanguineous Arab pedigree (Fig  1, A) with early-onset progressive BMF and myelodysplastic features.
Patient IV-1 was born prematurely and presented with severe anemia (hemoglobin, 3 g/dL) at birth, requiring immediate red blood cell transfusion. In her first 2 years of life, she was treated for recurrent upper respiratory tract infections. During one episode of severe infection, she was hospitalized, treated with intravenous antibiotics, and maintained on co-trimoxazole prophylaxis thereafter. She presented with BMF, short stature, and mild dysmorphic features, including thoracic asymmetry, a short left humerus, shortness of the metacarpal bone, dry skin, trigonocephaly, midface hypoplasia, gingiva hyperplasia, bilateral cataracts, and neurodevelopmental delay correlating with reduced cerebral volume (Fig 1, B , i-v; Table I ; and see Fig  E1, i-ii).
Patient IV-2 was delivered preterm and had anemia (hemoglobin, 2 g/dL), as well as cardiac insufficiency requiring immediate cardiopulmonary resuscitation and transfusion. Until his second year of life, 2 episodes of upper airway infection were noted, but no further infections developed under co-trimoxazole prophylaxis. In our center he presented with BMF, short stature, and dysmorphic features, including rhizomelic shortening of the arms, short fingers, bilateral protrusions on collar bones, dry skin, eczema, accessory papilla of the breast, noncompaction cardiomyopathy, midface hypoplasia, gingiva hyperplasia, delayed dentition, and neurodevelopmental delay associated with reduced cerebral volume (Fig 1, B, vi-x; Table I ; and see Fig E1, iii-vi). Table I provides a comprehensive synopsis of known clinical feature courses in human MYSM1 deficiency. In both patients BMF manifested with transfusion-dependent anemia, mild thrombocytopenia, lymphopenia, and moderate-to-severe neutropenia (see Fig E3 in this article's Online Repository at ww. jacionline.org). Further investigations on sequential bone marrow biopsy specimens of the patients revealed hypocellularity, increased adipocytes (Fig 2, A, i and v), siderosis (see Fig E2, A, i-iii, in this article's Online Repository at ww.jacionline.org), and reduced numbers of megakaryocytes with pleomorphic aberrations (see Fig E2, A, iv-vi) and normal myeloperoxidase levels (see Fig E2, A, vii-ix).
Bone marrow cytology showed dysplastic findings of red and white blood cell precursors. Pseudo-Pelger-Huet anomaly, as well as dysplastic findings of erythroid lineages, including multinucleated erythroblasts, cytoplasmic bridges, and ectopic nuclear morphology of erythroblasts, was noted in both patients. No blast excess was noted (Fig 2, A, ii-iv and vi-ix, and se Fig E2, B, i-iv). We searched for mutations in genes frequently mutated in patients with myelodysplastic syndromes but could not identify any in the exome data set (see Table E2 in this article's Online Repository at ww.jacionline. org). Cytogenetic studies in myeloid precursor cells, as well as in mitomycin C-treated lymphoid cells, showed a normal karyogram according to chromosomal banding. Array-CGH data did not reveal a disease-causing copy number variation (data not shown).
Immunostaining of bone marrow samples was performed to further characterize early B-and T-cell development. Lymphoid TdT 1 progenitor and early B-cell progenitor (CD10
) cell counts were markedly reduced, whereas CD3 1 cell counts were only mildly reduced (see Fig E2, A, xxxiv). In line with these data, immunophenotypic analysis disclosed marked reduction of peripheral CD19 ) B cells (Fig 2, B) . 9,10 T-cell immunophenotyping studies provided inconsistent results. At several time points, patients were slightly lymphopenic, with decreased absolute numbers of CD4 1 or CD8 1 T cells, but at other time points, relative and absolute numbers of T cells were normal (see Fig E4 and Table E3 in this article's Online Repository at ww.jacionline.org). Proliferation studies of B and T cells did not reveal any significant alterations compared with reference values of healthy age-matched children (see Table E3 ).
Comprehensive immunohematologic findings of all MYSM1-deficient patients are listed in Table E3 .
Identification of mutations in MYSM1
To investigate the underlying genetic alteration, we performed whole-exome sequencing in patients and their parents according to previously described protocols. 8 On variant filtering, we identified 9 potentially disease-causing variants (see Table E1 ). Of note, we found a variant in MYSM1 (NM_001085487: c.1168G>T: p.E390*) in a large homozygous interval. The sequence variant c.1168G>T could be confirmed by Sanger sequencing and segregated with the disease phenotype in an autosomal recessive inheritance pattern (Fig 3, A) . To study the consequences of this mutation leading to a premature stop codon in exon 9 (SWIRM domain), we generated anti-MYSM1 mAbs. As shown in Fig 3, B, MYSM1 could not be detected at the expected size in EBV-LCLs generated from the patients, whereas a 110-kDa band representing wild-type MYSM1 was seen in cells from parents.
Increased genotoxic stress in MYSM1-deficient cells
Murine Mysm1 deficiency results in increased genomic instability in blood cells.
11,12 Therefore we were interested to see whether MYSM1-deficient human patients had similar aberrations. We measured levels of phospho-histone H2AX (g-H2AX) as a marker for DNA damage in PBMCs and EBVLCLs. In MYSM1-deficient cells from patients, baseline levels of g-H2AX were increased in comparison with those of heterozygous parents and healthy donors (HDs) (Fig 3, C and D, and see Fig E5 in this article' s Online Repository at ww. jacionline.org). Upon UV irradiation-induced DNA damage, g-H2AX levels were upregulated independent of MYSM1 expression. In contrast to control cells, however, patients' cells had a slower decay rate and expressed high g-H2AX levels, even after 72 hours (Fig 3, D) .
The hematopoietic phenotype in Mysm1-deficient mice can be reverted by ablation of p53. 12, 13 Because p53 is linked to mitogenactivated protein kinase (MAPK) signaling, 14 we next hypothesized that increased cellular stress and genotoxicity in the setting of MYSM1 deficiency can be associated with increased activation of p38. We induced genotoxic stress in primary fibroblasts by means of UV irradiation and determined expression levels of phosphorylated p38 using Western blotting. Both MYSM1-deficient and control cells exhibited increased expression of p38 . E, WB analysis of p38 MAPK and phospho-p38 (Thr180/Tyr182) MAPK expression in primary fibroblasts of MYSM1-deficient patients and healthy control subjects in response to genotoxic stress (UV irradiation, 50 J/m 2 ; representative data of 2 independent experiments). F, Reconstitution analysis of p38 MAPK activation (phospho-p38, Thr180/Tyr182) in patient IV-2's primary fibroblast transduced by bicistronic lentiviruses expressing MYSM1-RFP or RFP only. After transduction, RFP-expressing cells were sorted and irradiated by UVC, and phospho-p38 and total p38 MAPK (Thr180/Tyr182) expression was analyzed by using WB (representative data of 3 independent experiments). The same results were observed on patient IV-1's MYSM1-corrected fibroblasts. G, Representative experiment of 3 independent flow cytometry-based cell-cycle analyses of MYSM1-deficient fibroblasts from a patient and a healthy control subject after UV irradiationinduced DNA damage (50 J/m 2 ).
and phosphorylated p38 in response to UVexposure. In contrast to HD cells, MYSM1-deficient cells had delayed re-equilibration of these stress-associated marks after 24 and 72 hours (Fig 3, E) . Moreover, MYSM1-deficient fibroblasts showed increased reactive oxygen species (ROS) production on UV treatment in comparison with control fibroblasts (see Fig E6 in this article' s Online Repository at ww.jacionline.org).
To unequivocally prove that the increased susceptibility to genotoxic stress is caused by MYSM1 deficiency, we aimed to reconstitute the cellular phenotype using retrovirus-mediated MYSM1 gene transfer. We cloned human MYSM1 in a bicistronic vector expressing red fluorescent protein (RFP) as a reporter gene and transduced fibroblasts from control subjects and patients. As shown in Fig 3, F, and Fig E7 in this article' s Online Repository at ww.jacionline.org, (partial) protection against the damaging effects induced by UV light, as seen by a more rapid decrease of phosphorylated p38 MAPK, was observed after MYSM1 transduction, whereas transduction of the control vector expressing RFP only had no effect.
In view of a putative role of MYSM1 in DNA-damage checkpoint control, 15 we next analyzed cell-cycle progression and the rate of apoptosis in MYSM1-deficient human fibroblast cells. Six hours after UV irradiation, we observed an arrest in the G1 phase and a reduced number of cells in the G2-M phase in all cells independent of MYSM1 expression. HD cells reequilibrated their regular distribution of cell-cycle phases, whereas MYSM1-deficient cells showed prolonged G1 arrest and a slower recovery (G2/M: 32.8% and 16.5%, respectively). The percentage of apoptotic cells (sub-G1) was increased in cells from patients in contrast to the percentage in cells from HDs (27.8% vs 11.9%; Fig  3, G) . In line with these data, MYSM1-deficient EBV-LCLs also had increased sensitivity to etoposide-induced apoptosis when compared with heterozygous parent or HD cells (see Fig E8 in this article's Online Repository at ww.jacionline.org).
Finally, we asked whether increased UV-induced genotoxic stress would lead to decreased clonogenic survival of fibroblasts. We plated 100 to 4000 cells followed by UV exposure and enumerated surviving cell clones after 20 days. MYSM1-deficient fibroblasts had reduced clonogenic growth when compared with cells from HDs (see Fig E9 in this article' s Online Repository at ww.jacionline.org).
Allogeneic hematopoietic stem cell transplantation
In view of progressive BMF with trilineage cytopenia, both patients underwent allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-matched adult family donors at the age of 42 and 23 months, respectively (see Fig E3) . The reducedintensity conditioning regimen 16 ), and alemtuzumab (0.4 mg/kg). Graftversus-host disease prophylaxis included cyclosporine and mycophenolate mofetil. The early posttransplantation course was uneventful in both patients. Two years after transplantation, they are full donor chimeras with normal peripheral blood counts and without signs of graft-versus-host disease (see Fig E3) . In patient IV-1 1 year after transplantation, hyperthyroidism (Graves-Basedow disease) has been diagnosed, probably reflecting a complication after transplantation. In patient IV-2 cardiomyopathy, which is currently treated with captopril, and neurological development show a favorable course.
DISCUSSION
We here report on clinical, immunologic, and molecular features in 2 siblings with MYSM1 deficiency. MYSM1 was originally discovered as a member of the histone H2A deubiquitinase complex coordinating histone acetylation and H1 dissociation in transcriptional regulation. 2 Subsequent studies in Mysm1-deficient mice have revealed that Mysm1 plays a critical role in B-cell maturation through derepression of transcription of early B-cell factor 1 (Ebf1), paired box 5 (Pax5), and other Blymphoid genes. 3 Jiang et al 3 suggested that MYSM1 mechanistically antagonizes action of the polycomb repressive complex 1 (PRC1) on the EBF1 promoter region, resulting in activation of transcription factor E2-a and PAX5. 3 In line with mouse data, we here report human MYSM1 deficiency causes BMF associated with B-cell deficiency. B-cell defect in MYSM1 deficiency has also recently been reported by 2 other groups. 6, 7 Further investigations of Mysm1-deficient mice disclosed that the epigenetic regulatory function of Mysm1 is not restricted to B cells but might also affect other immune and nonimmune cells. 5, [17] [18] [19] [20] Moreover, Panda et al 21 reported that MYSM1, beyond its crucial role in the nucleus, can function in the cytoplasm as a deubiquitinating enzyme regulating innate immunity responses. In line with these data, we also observed impaired vaccination and antibody titers, but in contrast, T-cell immunity was not affected in our patients.
DNA damage triggers cellular repair activities associated with accumulation of ubiquitin-H2A at g-H2AX containing foci. 22, 23 Upon successful completion of DNA repair, dephosphorylation and removal of g-H2AX and ubiquitin-H2A are essential for resuming coordinated progression of the cell cycle. 24, 25 Deubiquinating enzymes, such as ubiquitin-specific peptidase 3 (Usp3) and Usp16, might regulate the cellular response toward DNA damage. [26] [27] [28] Our data show that in the absence of MYSM1, the cellular re-equilibration of cell-cycle progression is perturbed, suggesting that MYSM1 is involved in DNA damage-induced repair.
Cross-activation of p38 and p53 has been shown to play a key role in stress responses, in particular after genotoxic stress. 14, [29] [30] [31] When Nijnik et al 11 discovered increased levels of g-H2AX, ROS, and p53 in Mysm1-deficient murine hematopoietic cells, they hypothesized a critical role for p53 linked to Mysm1. In fact, the generation of Mysm1 2/2 p53 2/2 double-deficient mice confirmed this idea because the hematopoietic defects observed in Mysm1-deficient mice were completely reversed in the absence of p53. 12, 13 Subsequent studies have recently shown that p53 and Mysm1 colocalize to genomic loci known to be transcriptionally controlled by p53, 32 suggesting that Mysm1 controls accessibility of defined genomic loci to transcription factors. However, the exact sequence of events remains to be elucidated. Our data show that MYSM1-deficient cells are characterized by a state of increased stress (evidence by phosphorylation of p38) and delayed return to a coordinated cell-cycle progression. We assume that these effects are linked to both altered histone deubiquitination and imbalanced transcriptional regulation, but at this point, we cannot yet define the molecular steps in greater detail.
Two previous reports of patients with MYSM1 deficiency have implicated its importance in adequate hematopoiesis and B-cell development. 6, 7 We expand on these observations and show that MYSM1 deficiency is associated with developmental aberrations, myelodysplastic features, and increased susceptibility to genotoxic stress. We also document that the hematopoietic defects in patients with MYSM1 deficiency can be cured by allogeneic HSCT. Conditioning regimens for allogeneic HSC transplants must be carefully selected in patients with increased susceptibility to genotoxicity, such as Fanconi anemia and Nijmegen breakage syndrome. Our regimen based on fludarabine and treosulfan appeared to be safe and effective for stable engraftment of allogeneic stem cells without undue toxicity.
In summary, our results expand the spectrum of rare BMF syndromes associated with immunodeficiency and developmental aberrations.
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Key messages
d MYSM1 deficiency causes B-cell immunodeficiency associated with complex developmental aberrations and inherited BMF syndrome.
d MYSM1 controls genotoxic stress responses.
d The immunologic and hematologic aberrations in patients with MYSM1 deficiency can be cured by using allogeneic HSCT.
